Bibliography
- Dy GK, Adjei AA. Obstacles and opportunities in the clinical development of targeted therapeutics. Prog Drug Res 2005;63:19-41
- Murdoch D, Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol 2008;20:104-11
- Lippman SM, Heymach JV. The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res 2007;13:4035-41
- Youssoufian H, Rowinsky EK. A remedy for biomarker addiction: back to rational anticancer drug development. Nat Clin Pract Oncol 2007;4:264-5
- Safavy A. Recent developments in taxane drug delivery. Curr Drug Deliv 2008;5:42-54
- Zhu F, Zheng CJ, Han LY, et al. Trends in the exploration of anticancer targets and strategies in enhancing the efficacy of drug targeting. Curr Mol Pharmacol 2008;1:213-32
- Fan F, Wood KV. Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol 2007;5:127-36
- Neamati N, Barchi JJ Jr. New paradigms in drug design and discovery. Curr Top Med Chem 2002;2:211-27
- Plasencia C, Dayam R, Wang Q, et al. Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Mol Cancer Ther 2005;4:1105-13
- Al-Mawsawi LQ, Dayam R, Taheri L, et al. Discovery of novel non-cytotoxic salicylhydrazide containing HIV-1 integrase inhibitors. Bioorg Med Chem Lett 2007;17:6472-5
- Grande F, Aiello F, Grazia OD, et al. Synthesis and antitumor activities of a series of novel quinoxalinhydrazides. Bioorg Med Chem 2007;15:288-94
- Deng J, Taheri L, Grande F, et al. Discovery of novel anticancer compounds based on a quinoxalinehydrazine pharmacophore. ChemMedChem 2008;3:1677-86
- Cao X, Plasencia C, Kanzaki A, et al. Elucidation of the molecular mechanisms of a salicylhydrazide class of compounds by proteomic analysis. Curr Cancer Drug Targets 2009. In press
- Oshima T, Cao X, Grande F, et al. Combination effects of SC144 and cytotoxic anti-cancer agents. Anti Cancer Drugs 2009. In press
- Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44:235-49
- Buick RN, Pullano R, Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985;45:3668-76
- Hamaguchi K, Godwin AK, Yakushiji M, et al. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 1993;53:5225-32
- Carmichael J, DeGraff WG, Gazdar AF, et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-42
- Munshi A, Hobbs M, Meyn RE. Clonogenic cell survival assay. Methods Mol Med 2005;110:21-8
- Reich MF, Fabio PF, Lee VJ, et al. Pyrido[3,4-e]-1,2,4-triazines and related heterocycles as potential antifungal agents. J Med Chem 1989;32:2474-85
- Campiani G, Morelli E, Gemma S, et al. Pyrroloquinoxaline derivatives as high-affinity and selective 5-HT(3) receptor agonists: synthesis, further structure-activity relationships, and biological studies. J Med Chem 1999;42:4362-79
- Guillon J, Grellier P, Labaied M, et al. Synthesis, antimalarial activity, and molecular modeling of new pyrrolo[1,2-a]quinoxalines, bispyrrolo[1,2-a]quinoxalines, bispyrido[3,2-e]pyrrolo[1,2-a] pyrazines, and bispyrrolo[1,2-a]thieno[3,2-e]pyrazines. J Med Chem 2004;47:1997-2009
- Kashulin IA, Nifant'ev IE. Efficient method for the synthesis of hetarenoindanones based on 3-arylhetarenes and their conversion into hetarenoindenes. J Org Chem 2004;69:5476-9
- Van Hooser A, Goodrich DW, Allis CD, et al. Histone H3 phosphorylation is required for the initiation, but not maintenance, of mammalian chromosome condensation. J Cell Sci 1998;111(Pt 23):3497-506
- Plasencia C, Grande F, Oshima T, et al. Discovery of a novel quinoxalinhydrazide with a broad-spectrum anticancer activity. Cancer Biol Ther 2009;8:458-65